GCM
CBAY

Graham Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Graham Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-68,579
Closed -$751K – 1352
2023
Q2 		$751K Sell
68,579
-76,395
-53% -$711K 0.02% 440
2023
Q1 		$1.26M Buy
144,974
+117,896
+435% +$944K 0.04% 423
2022
Q4 		$170K Buy
+27,078
New +$103K 0.01% 979

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Graham Capital Management's CBAY Position: Q3 2023 in Review

Graham Capital Management sold out of Cymabay Therapeutics (CBAY) in Q3 2023, closing a stake of 68,579 shares — an estimated $751K sold.

Graham Capital Management first reported a position in CBAY in Q4 2022 and held it in 3 quarters. The position peaked at $1.26M in Q1 2023. 189 funds tracked by Wall St. Rank hold CBAY as of Q3 2023.

  • Graham Capital Management reported no remaining Cymabay Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Graham Capital Management sold 68,579 Cymabay Therapeutics shares in Q3 2023, an estimated $751K.
  • Graham Capital Management first reported a position in Cymabay Therapeutics in Q4 2022 and held it in 3 quarters.
  • Graham Capital Management's Cymabay Therapeutics position peaked at $1.26M in Q1 2023.
  • 189 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2023.

Based on Graham Capital Management's 13F filing for Q3 2023, filed 22 Nov 2023.